Phase 4
N=15
Healing Ointment Usage Post-surgical Procedure
Surgical Wound
Bottom Line
View on ClinicalTrials.gov: NCT05686928 ↗Enrolled (actual)
15
Serious AEs
0.0%
Results posted
May 2025
Primary outcome: Primary: Objective Erythema Assessment Using Clinical Grading Analog Scale — 0.8; 0.83; 0.75; 0.29 score on a scale
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 4
- Interventions
- Cetaphil Healing Ointment (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Galderma R&D
- Primary completion
- Oct 2022
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Objective Erythema Assessment Using Clinical Grading Analog Scale |
0.8; 0.83; 0.75; 0.29 | — |
| PRIMARY Objective Edema Assessment Using Clinical Grading Analog Scale |
0.03; 0.5; 0; 0 | — |
| PRIMARY Objective Overall Wound Appearance Assessment Using Clinical Grading Analog Scale |
0.57; 2.13; 1.36; 0.54 | — |
| PRIMARY Objective Scabbing/Crusting Assessment Using Clinical Grading Analog Scale |
0.53; 0; 0.14; 0 | — |
| PRIMARY Subjective Burning Assessment Using an Analog Scale |
0.2; 0; 0.04; 0 | — |
| PRIMARY Subjective Itching Assessment Using an Analog Scale |
0.53; 0.07; 0.04; 0 | — |
| PRIMARY Subjective Pain Assessment Using an Analog Scale |
0.13; 0; 0; 0 | — |
| SECONDARY Subject Satisfaction Using a Self-assessment Questionnaire |
12; 12; 11; 10 | — |
| SECONDARY Subject Satisfaction Using a Self-assessment Questionnaire |
12; 12; 11; 10 | — |
Summary
To evaluate benefits of a Healing Ointment in skin improvement after dermatologic procedures
Eligibility Criteria
Inclusion Criteria
- Subject who undergo Mohs surgery, skin biopsy, excision on the head/neck or body
- Ability of giving consent for participation in the study
- Agreement to adhere to the procedures and requirements of the study and to report to the institute on the day(s) and at the time(s) scheduled for the assessments
Exclusion Criteria
- History of allergy or hypersensitivity to cosmetic ingredients
- Pregnant, planning pregnancy during the course of the study or breastfeeding
- Subject with a history of keloids or hypertrophic scars
- Presence of tattoo and/or scar in the treatment area that in the investigator's opinion would interfere with study assessments
- Subjects with history of or the presence of any skin condition/disease that might interfere with the diagnosis or evaluation of study parameters (i.e., atopic dermatitis, eczema, psoriasis, seborrheic dermatitis) at the discretion of the investigator
- Subjects with inability to comply with all study protocol restrictions and visits
Data sourced from ClinicalTrials.gov (NCT05686928). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.